Conference Material > Poster
Cazes C, Phelan KPQ, Hubert V, Boubacar H, Tshibangu G, et al.
MSF Scientific Days International 2021: Research. 2021 May 18
Conference Material > Poster
Cazes C, Sirna F, Phelan KPQ, Hubert V, Tshiala BK, et al.
MSF Scientific Days International 2022. 2022 May 9; DOI:10.57740/cbcx-vk63
Conference Material > Poster
Cazes C, Alitanou R, Phelan KPQ, Hubert V, Kalenga Tshiala B, et al.
MSF Scientific Day International 2023. 2023 June 7; DOI:10.57740/y209-ga31
Journal Article > ResearchFull Text
Sci Rep. 2020 August 6; Volume 10 (Issue 1); DOI:10.1038/s41598-020-69987-9
Fabiansen C, Cichon B, Yaméogo CW, Iuel-Brockdorf AS, Phelan KPQ, et al.
Sci Rep. 2020 August 6; Volume 10 (Issue 1); DOI:10.1038/s41598-020-69987-9
Children with moderate acute malnutrition (MAM) are treated based on low weight-for-length z-score (WLZ), low mid-upper arm circumference (MUAC) or both. This study aimed to assess associations of admission criteria and body composition (BC), to improve treatment of MAM. We undertook a cross-sectional study among 6-23 months old Burkinabe children with MAM. Fat-free (FFM) and fat mass (FM) were determined by deuterium dilution and expressed as FFM (FFMI) and FM index (FMI). Of 1,489 children, 439 (29.5%) were recruited by low MUAC only (MUAC-O), 734 (49.3%) by low WLZ and low MUAC (WLZ-MUAC) and 316 (21.2%) by low WLZ only (WLZ-O). Thus, 1,173 (78.8%) were recruited by low MUAC, with or without low WLZ (ALL-MUAC). After adjustments, WLZ-O had 89 g (95% confidence interval (CI) 5; 172) lower FFM compared to MUAC-O. Similarly, WLZ-O had 0.89 kg/m2 (95% CI 0.77; 1.01) lower FFMI compared to MUAC-O, whereas there was no difference for FMI. However, boys included by WLZ-O compared to MUAC-O had 0.21 kg/m2 (95% CI 0.05; 0.38) higher FMI. In contrast, girls included by WLZ-O had 0.17 (95% CI 0.01; 0.33) kg/m2 lower FMI compared to MUAC-O (interaction, p = 0.002). We found that different criteria for admission into MAM treatment programmes select children with differences in BC, especially FFMI.
Journal Article > ResearchAbstract
Appetite. 2012 August 4; Volume 59 (Issue 3); DOI:10.1016/j.appet.2012.07.019
Cohuet S, Marquer C, Shepherd S, Captier V, Langendorf C, et al.
Appetite. 2012 August 4; Volume 59 (Issue 3); DOI:10.1016/j.appet.2012.07.019
Few studies have looked at consumption of Ready-to-Use-Supplementary-Foods (RUSFs) during a nutritional emergency. Here, we describe the use and acceptability of RUSF within households in four districts of the region of Maradi, Niger during large scale preventive distributions with RUSF in 2010 targeted at children 6-35months of age. Our study comprised both quantitative and qualitative components to collect detailed information and to allow in-depth interviews. We performed a cross-sectional survey in 16 villages between two monthly distributions of RUSF (October-November 2010). All households with at least one child who received RUSF were included and a total of 1842 caregivers were interviewed using a structured questionnaire. Focus groups and individual interviews of 128 caregivers were conducted in eight of the selected villages. On average, 24.7% of households reported any sharing of RUSF within the household. Sharing practices outside the household remained rare. Most of the sharing reported occurred among children under 5years of age living in the household. On average, 91% of caregivers in all districts rated the child's appreciation of the products as good or very good. Program planning may need to explicitly accounting for the sharing of products among children under 5 within household.
Conference Material > Abstract
Cazes C, Phelan KPQ, Hubert V, Boubacar H, Bozama LI, et al.
MSF Scientific Days International 2021: Research. 2021 May 19
INTRODUCTION
The Optimising MAlnutrition treatment (OptiMA) strategy aims to simplify current malnutrition treatment protocols for children with mid-upper arm circumference (MUAC)<125mm or oedema, by supplementing with one product—ready-to-use therapeutic food (RUTF), using gradually reducing doses as a child’s weight and MUAC increases.
METHODS
This non-inferiority, randomized controlled trial was conducted in Kasai province, Democratic Republic of Congo (DRC). It compared the OptiMA strategy with the effective standard DRC protocol, using increasing weight doses of RUTF for treating severe acute malnutrition (SAM) and ready to use supplementary food (RUSF) at fixed dose for moderate acute malnutrition. Children aged 6–59 months with MUAC<125mm or weight-for-height Z score<−3 or oedema, and without medical complications, were randomized to either OptiMA or the standard protocol, and followed up for six months. Primary outcome was a composite indicator at 6 months’ follow-up: child alive, not acutely malnourished per the study definition, and without any additional episode of acute malnutrition throughout the observation period. Non-inferiority was determined if the upper boundary of the 95% confidence interval (CI) for the difference between randomized arms in the proportion of children with favourable outcome was less than 10%, for both intention-to-treat (ITT) and per-protocol (PP) analyses. Superiority was determined if the upper boundary of the 95% CI for this difference was lower than 0%.
ETHICS
This study was approved by the National Congolese Health Ethics Committee and by the Ethics Evaluation Committee of Inserm, the French National Institute for Health and Medical Research. ClinicalTrials.gov number, NCT03751475.
RESULTS
Between July 2019 and July 2020, 981 children were enrolled. 896 children were included in ITT analysis, with 450 in the OptiMA arm and 446 standard; 792 were included in PP analysis. Over the entire follow-up, 450 (100%) children under OptiMA received RUTF treatment while under the standard protocol, 315 (71%) received RUTF or RUSF or both. ITT analysis found that 325 (72.2%) children had favourable outcome under OptiMA versus 282 (63.2%) in the standard arm (difference: -9.2%, 95%CI -15.9% to -2.0%). Under OptiMA, weight gain was greater (median weight gain, 1700g versus 1600g, p= 0.003), the nutritional treatment consumption lower (median of 64 of RUTF versus 102 sachets of RUTF/RUSF under standard; p= 0.018). Median time to recovery (i.e., MUAC>124mm without oedema for two consecutive visits) was lower under OptiMA than under standard: 5 weeks (95%CI 5–5) versus 9 weeks (95%CI 8–10), p<0.001. We did not observe a difference in hospitalization rates (10% OptiMA, 7% standard, p=0.228) or mortality rates (0.2% in both arms).
CONCLUSION
OptiMA led to better anthropometric status over a six-month period and expanded access to treatment, whilst the standard protocol partially addressed global acute malnutrition with higher consumption of nutritional products used in the trial. Our findings suggest it may be beneficial to address global acute malnutrition in one program using one product at a gradually adjusted dose.
CONFLICTS OF INTEREST
None declared.
The Optimising MAlnutrition treatment (OptiMA) strategy aims to simplify current malnutrition treatment protocols for children with mid-upper arm circumference (MUAC)<125mm or oedema, by supplementing with one product—ready-to-use therapeutic food (RUTF), using gradually reducing doses as a child’s weight and MUAC increases.
METHODS
This non-inferiority, randomized controlled trial was conducted in Kasai province, Democratic Republic of Congo (DRC). It compared the OptiMA strategy with the effective standard DRC protocol, using increasing weight doses of RUTF for treating severe acute malnutrition (SAM) and ready to use supplementary food (RUSF) at fixed dose for moderate acute malnutrition. Children aged 6–59 months with MUAC<125mm or weight-for-height Z score<−3 or oedema, and without medical complications, were randomized to either OptiMA or the standard protocol, and followed up for six months. Primary outcome was a composite indicator at 6 months’ follow-up: child alive, not acutely malnourished per the study definition, and without any additional episode of acute malnutrition throughout the observation period. Non-inferiority was determined if the upper boundary of the 95% confidence interval (CI) for the difference between randomized arms in the proportion of children with favourable outcome was less than 10%, for both intention-to-treat (ITT) and per-protocol (PP) analyses. Superiority was determined if the upper boundary of the 95% CI for this difference was lower than 0%.
ETHICS
This study was approved by the National Congolese Health Ethics Committee and by the Ethics Evaluation Committee of Inserm, the French National Institute for Health and Medical Research. ClinicalTrials.gov number, NCT03751475.
RESULTS
Between July 2019 and July 2020, 981 children were enrolled. 896 children were included in ITT analysis, with 450 in the OptiMA arm and 446 standard; 792 were included in PP analysis. Over the entire follow-up, 450 (100%) children under OptiMA received RUTF treatment while under the standard protocol, 315 (71%) received RUTF or RUSF or both. ITT analysis found that 325 (72.2%) children had favourable outcome under OptiMA versus 282 (63.2%) in the standard arm (difference: -9.2%, 95%CI -15.9% to -2.0%). Under OptiMA, weight gain was greater (median weight gain, 1700g versus 1600g, p= 0.003), the nutritional treatment consumption lower (median of 64 of RUTF versus 102 sachets of RUTF/RUSF under standard; p= 0.018). Median time to recovery (i.e., MUAC>124mm without oedema for two consecutive visits) was lower under OptiMA than under standard: 5 weeks (95%CI 5–5) versus 9 weeks (95%CI 8–10), p<0.001. We did not observe a difference in hospitalization rates (10% OptiMA, 7% standard, p=0.228) or mortality rates (0.2% in both arms).
CONCLUSION
OptiMA led to better anthropometric status over a six-month period and expanded access to treatment, whilst the standard protocol partially addressed global acute malnutrition with higher consumption of nutritional products used in the trial. Our findings suggest it may be beneficial to address global acute malnutrition in one program using one product at a gradually adjusted dose.
CONFLICTS OF INTEREST
None declared.
Journal Article > ResearchFull Text
PLOS Med. 2020 December 23; Volume 17 (Issue 12); e1003442.; DOI:10.1371/journal.pmed.1003442
Olsen MF, Iuel-Brockdorf AS, Yaméogo CW, Cichon B, Fabiansen C, et al.
PLOS Med. 2020 December 23; Volume 17 (Issue 12); e1003442.; DOI:10.1371/journal.pmed.1003442
BACKGROUND
Lipid-based nutrient supplements (LNS) and corn–soy blends (CSBs) with varying soy and milk content are used in treatment of moderate acute malnutrition (MAM). We assessed the impact of these supplements on child development.
METHODS AND FINDINGS
We conducted a randomised 2 × 2 × 3 factorial trial to assess the effectiveness of 12 weeks’ supplementation with LNS or CSB, with either soy isolate or dehulled soy, and either 0%, 20%, or 50% of protein from milk, on child development among 6–23-month-old children with MAM. Recruitment took place at 5 health centres in Province du Passoré, Burkina Faso between September 2013 and August 2014. The study was fully blinded with respect to soy quality and milk content, while study participants were not blinded with respect to matrix. This analysis presents secondary trial outcomes: Gross motor, fine motor, and language development were assessed using the Malawi Development Assessment Tool (MDAT). Of 1,609 children enrolled, 54.7% were girls, and median age was 11.3 months (interquartile range [IQR] 8.2–16.0). Twelve weeks follow-up was completed by 1,548 (96.2%), and 24 weeks follow-up was completed by 1,503 (93.4%); follow-up was similar between randomised groups. During the study, 4 children died, and 102 children developed severe acute malnutrition (SAM). There was no difference in adverse events between randomised groups. At 12 weeks, the mean MDAT z-scores in the whole cohort had increased by 0.33 (95% CI: 0.28, 0.37), p < 0.001 for gross motor; 0.26 (0.20, 0.31), p < 0.001 for fine motor; and 0.14 (0.09, 0.20), p < 0.001 for language development. Children had larger improvement in language z-scores if receiving supplements with milk (20%: 0.09 [−0.01, 0.19], p = 0.08 and 50%: 0.11 [0.01, 0.21], p = 0.02), although the difference only reached statistical significance for 50% milk. Post hoc analyses suggested that this effect was specific to boys (interaction p = 0.02). The fine motor z-scores were also improved in children receiving milk, but only when 20% milk was added to CSB (0.18 [0.03, 0.33], p = 0.02). Soy isolate over dehulled soy increased language z-scores by 0.07 (−0.01, 0.15), p = 0.10, although not statistically significant. Post hoc analyses suggested that LNS benefited gross motor development among boys more than did CSB (interaction p = 0.04). Differences between supplement groups did not persist at 24 weeks, but MDAT z-scores continued to increase post-supplementation. The lack of an unsupplemented control group limits us from determining the overall effects of nutritional supplementation for children with MAM.
CONCLUSIONS
In this study, we found that child development improved during and after supplementation for treatment of MAM. Milk protein was beneficial for language and fine motor development, while suggested benefits related to soy quality and supplement matrix merit further investigation. Supplement-specific effects were not found post-intervention, but z-scores continued to improve, suggesting a sustained overall effect of supplementation.
Lipid-based nutrient supplements (LNS) and corn–soy blends (CSBs) with varying soy and milk content are used in treatment of moderate acute malnutrition (MAM). We assessed the impact of these supplements on child development.
METHODS AND FINDINGS
We conducted a randomised 2 × 2 × 3 factorial trial to assess the effectiveness of 12 weeks’ supplementation with LNS or CSB, with either soy isolate or dehulled soy, and either 0%, 20%, or 50% of protein from milk, on child development among 6–23-month-old children with MAM. Recruitment took place at 5 health centres in Province du Passoré, Burkina Faso between September 2013 and August 2014. The study was fully blinded with respect to soy quality and milk content, while study participants were not blinded with respect to matrix. This analysis presents secondary trial outcomes: Gross motor, fine motor, and language development were assessed using the Malawi Development Assessment Tool (MDAT). Of 1,609 children enrolled, 54.7% were girls, and median age was 11.3 months (interquartile range [IQR] 8.2–16.0). Twelve weeks follow-up was completed by 1,548 (96.2%), and 24 weeks follow-up was completed by 1,503 (93.4%); follow-up was similar between randomised groups. During the study, 4 children died, and 102 children developed severe acute malnutrition (SAM). There was no difference in adverse events between randomised groups. At 12 weeks, the mean MDAT z-scores in the whole cohort had increased by 0.33 (95% CI: 0.28, 0.37), p < 0.001 for gross motor; 0.26 (0.20, 0.31), p < 0.001 for fine motor; and 0.14 (0.09, 0.20), p < 0.001 for language development. Children had larger improvement in language z-scores if receiving supplements with milk (20%: 0.09 [−0.01, 0.19], p = 0.08 and 50%: 0.11 [0.01, 0.21], p = 0.02), although the difference only reached statistical significance for 50% milk. Post hoc analyses suggested that this effect was specific to boys (interaction p = 0.02). The fine motor z-scores were also improved in children receiving milk, but only when 20% milk was added to CSB (0.18 [0.03, 0.33], p = 0.02). Soy isolate over dehulled soy increased language z-scores by 0.07 (−0.01, 0.15), p = 0.10, although not statistically significant. Post hoc analyses suggested that LNS benefited gross motor development among boys more than did CSB (interaction p = 0.04). Differences between supplement groups did not persist at 24 weeks, but MDAT z-scores continued to increase post-supplementation. The lack of an unsupplemented control group limits us from determining the overall effects of nutritional supplementation for children with MAM.
CONCLUSIONS
In this study, we found that child development improved during and after supplementation for treatment of MAM. Milk protein was beneficial for language and fine motor development, while suggested benefits related to soy quality and supplement matrix merit further investigation. Supplement-specific effects were not found post-intervention, but z-scores continued to improve, suggesting a sustained overall effect of supplementation.
Conference Material > Poster
Cazes C, Phelan KPQ, Hubert V, Boubacar H, Tshibangu G, et al.
MSF Scientific Days International 2021: Research. 2021 May 18
Journal Article > ResearchFull Text
Am J Clin Nutr. 2016 January 6; Volume 103 (Issue 2); 415-21.; DOI:10.3945/ajcn.115.124644
Fabiansen C, Phelan KPQ, Cichon B, Ritz C, Briend A, et al.
Am J Clin Nutr. 2016 January 6; Volume 103 (Issue 2); 415-21.; DOI:10.3945/ajcn.115.124644
BACKGROUND
The management of children with moderate acute malnutrition (MAM) is based on food supplementation in outpatient programs. When midupper arm circumference (MUAC) is used as the sole admission criterion, it is common practice to exclude children with lengths <67 cm from treatment. The WHO calls for research to determine the treatment effect among children with MAM included by MUAC and aged ≥6 mo with lengths <67 cm.
OBJECTIVE
We hypothesized that among children given supplementary feeding based on an MUAC of 115-124 mm as the sole criterion, there would be no difference in growth rate between children <67 cm and those ≥67 cm in length at program admission.
DESIGN
This was an observational study nested in a randomized trial that investigated the effectiveness of new formulations of corn-soy blend and lipid-based nutrient supplements. Children aged 6-23 mo were included if their MUAC was between 115 and 124 mm but with a weight-for-height z score (WHZ) ≥-2. This cohort was divided into 2 groups by length at admission: <67 cm ("short") and ≥67 cm ("long"). Linear mixed-effects models and regression models were used to compare gains in weight and MUAC while adjusting for intervention, season, sex, age, and site.
RESULTS
Weight-gain velocity (expressed as g · kg(-1) · d(-1)) and MUAC-gain velocity (expressed as 0.01 mm · cm(-1) · d(-1)) were not different between short and long children. Weight-gain velocity was slightly higher in the shortest quartile of length (P = 0.03), whereas there was no effect modification by stunting across length quartiles (P = 0.32).
CONCLUSION
We found no evidence of a difference in percentage of weight gain or weight-gain velocity during supplementary feeding in short or long children aged 6-23 mo. We recommend a policy change to include children <67 cm in supplementary feeding programs if their MUAC is between 115 and 124 mm and their WHZ is ≥-2. This could benefit millions of children currently excluded from supplementary feeding. This trial was registered at www.controlled-trials.com as ISRCTN42569496.
The management of children with moderate acute malnutrition (MAM) is based on food supplementation in outpatient programs. When midupper arm circumference (MUAC) is used as the sole admission criterion, it is common practice to exclude children with lengths <67 cm from treatment. The WHO calls for research to determine the treatment effect among children with MAM included by MUAC and aged ≥6 mo with lengths <67 cm.
OBJECTIVE
We hypothesized that among children given supplementary feeding based on an MUAC of 115-124 mm as the sole criterion, there would be no difference in growth rate between children <67 cm and those ≥67 cm in length at program admission.
DESIGN
This was an observational study nested in a randomized trial that investigated the effectiveness of new formulations of corn-soy blend and lipid-based nutrient supplements. Children aged 6-23 mo were included if their MUAC was between 115 and 124 mm but with a weight-for-height z score (WHZ) ≥-2. This cohort was divided into 2 groups by length at admission: <67 cm ("short") and ≥67 cm ("long"). Linear mixed-effects models and regression models were used to compare gains in weight and MUAC while adjusting for intervention, season, sex, age, and site.
RESULTS
Weight-gain velocity (expressed as g · kg(-1) · d(-1)) and MUAC-gain velocity (expressed as 0.01 mm · cm(-1) · d(-1)) were not different between short and long children. Weight-gain velocity was slightly higher in the shortest quartile of length (P = 0.03), whereas there was no effect modification by stunting across length quartiles (P = 0.32).
CONCLUSION
We found no evidence of a difference in percentage of weight gain or weight-gain velocity during supplementary feeding in short or long children aged 6-23 mo. We recommend a policy change to include children <67 cm in supplementary feeding programs if their MUAC is between 115 and 124 mm and their WHZ is ≥-2. This could benefit millions of children currently excluded from supplementary feeding. This trial was registered at www.controlled-trials.com as ISRCTN42569496.
Conference Material > Abstract
Daures M, Phelan KPQ, Issoufou M, Kouanda S, Sawadogo O, et al.
MSF Scientific Days International 2020: Research. 2020 May 26
INTRODUCTION
The Optimizing Treatment for Acute Malnutrition (OptiMA) strategy trains mothers to use mid-upper arm circumference (MUAC) bracelets for screening, and targets treatment to children with MUAC<125mm or oedema, with one product, ready-to-use therapeutic food (RUTF), at a gradually tapering dose, based on child weight and MUAC status. We aimed to determine incidence of relapse and associated factors among children who recovered under the OptiMA protocol.
METHODS
We conducted a prospective cohort study among all children who recovered from malnutrition under OptiMA at randomly selected health centers between April and November 2017. A one-stage clustered and stratified sampling design randomly selected 12 of the 54 health centers where the OptiMA strategy was implemented. Recovered children were then seen at home by community health workers every two weeks for three months. Relapse was defined as a child who initially recovered after OptiMA management but subsequently had a MUAC<125mm at any home visit. Overall incidence of relapse, and by MUAC category at admission and discharge, was calculated with 95% confidence intervals (CI). Multivariable survival analysis was run using a shared frailty model, using a random effect on health facilities to identify associated factors.
ETHICS
This study was approved by the Ethics Committee for Health Research, Burkina Faso.
Results
Of 758 eligible children, 118 (15.6%) were lost to follow-up. 640 (84.5%) children were analysed, with a global incidence of relapse (MUAC<125mm at three months post-recovery) of 6.9% (95%CI 5.1-8.8), including 0.5% (95%CI 0.1-1.0) who relapsed with MUAC<115mm. Median time to relapse was 42 days (interquartile range 28.0-59.5). Most children (84.4%) relapsed with a MUAC of 120-124mm. Relapse was positively associated with low MUAC at discharge, adjusted hazard ratio (aHR) 2.75 (95%CI 1.11-6.83) for MUAC 126-128mm, and aHR 5.54 (95%CI 1.98-15.52) for MUAC=125mm, as compared to children with MUAC>=129mm. Relapse was also associated with having been hospitalised at any point during treatment, aHR 1.98 (95%CI 0.93-4.23).
CONCLUSIONS
Incidence of relapse following recovery under OptiMA was relatively low in this context, but the lack of a standard relapse definition does not allow comparison with other settings. The decrease in incidence of relapse among children with MUAC>=129mm at exit is in line with previous studies showing that MUAC>130mm at discharge reduced risk of mortality one year post-recovery. This finding challenges definition of the threshold for discharge under OptiMA, and standard protocols, of 125mm. Re-training caretakers at discharge to screen their children for relapse by MUAC at home could also be more effective at detecting early relapse, and less costly, than home visits by CHWs. One limitation to this study is the high percentage of children lost to follow up could impact on validity of the results. Further work is needed to define the most effective MUAC discharge threshold.
CONFLICTS OF INTEREST
KP serves on the Social Purposes Advisory Commission of Nutriset, a producer of lipid-based nutrient supplement products. Other authors declare no conflicts of interest.
The Optimizing Treatment for Acute Malnutrition (OptiMA) strategy trains mothers to use mid-upper arm circumference (MUAC) bracelets for screening, and targets treatment to children with MUAC<125mm or oedema, with one product, ready-to-use therapeutic food (RUTF), at a gradually tapering dose, based on child weight and MUAC status. We aimed to determine incidence of relapse and associated factors among children who recovered under the OptiMA protocol.
METHODS
We conducted a prospective cohort study among all children who recovered from malnutrition under OptiMA at randomly selected health centers between April and November 2017. A one-stage clustered and stratified sampling design randomly selected 12 of the 54 health centers where the OptiMA strategy was implemented. Recovered children were then seen at home by community health workers every two weeks for three months. Relapse was defined as a child who initially recovered after OptiMA management but subsequently had a MUAC<125mm at any home visit. Overall incidence of relapse, and by MUAC category at admission and discharge, was calculated with 95% confidence intervals (CI). Multivariable survival analysis was run using a shared frailty model, using a random effect on health facilities to identify associated factors.
ETHICS
This study was approved by the Ethics Committee for Health Research, Burkina Faso.
Results
Of 758 eligible children, 118 (15.6%) were lost to follow-up. 640 (84.5%) children were analysed, with a global incidence of relapse (MUAC<125mm at three months post-recovery) of 6.9% (95%CI 5.1-8.8), including 0.5% (95%CI 0.1-1.0) who relapsed with MUAC<115mm. Median time to relapse was 42 days (interquartile range 28.0-59.5). Most children (84.4%) relapsed with a MUAC of 120-124mm. Relapse was positively associated with low MUAC at discharge, adjusted hazard ratio (aHR) 2.75 (95%CI 1.11-6.83) for MUAC 126-128mm, and aHR 5.54 (95%CI 1.98-15.52) for MUAC=125mm, as compared to children with MUAC>=129mm. Relapse was also associated with having been hospitalised at any point during treatment, aHR 1.98 (95%CI 0.93-4.23).
CONCLUSIONS
Incidence of relapse following recovery under OptiMA was relatively low in this context, but the lack of a standard relapse definition does not allow comparison with other settings. The decrease in incidence of relapse among children with MUAC>=129mm at exit is in line with previous studies showing that MUAC>130mm at discharge reduced risk of mortality one year post-recovery. This finding challenges definition of the threshold for discharge under OptiMA, and standard protocols, of 125mm. Re-training caretakers at discharge to screen their children for relapse by MUAC at home could also be more effective at detecting early relapse, and less costly, than home visits by CHWs. One limitation to this study is the high percentage of children lost to follow up could impact on validity of the results. Further work is needed to define the most effective MUAC discharge threshold.
CONFLICTS OF INTEREST
KP serves on the Social Purposes Advisory Commission of Nutriset, a producer of lipid-based nutrient supplement products. Other authors declare no conflicts of interest.